# US 2022/0275342 A1 · Dissolvable and degradable artificial circulation systems for large volume tissues

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0275342 A1
- Document ID: US20220275342A1
- Status: Published application
- Kind: A1
- Application number: 17/625,686
- Filed: 2020-07-06
- Published: 2022-09-01
- Earliest claimed: 2019-07-09
- Applicants: Board of Regents of the University of Nebraska
- Inventors: Yuguo LEI; Qiang LI; Ou WANG
- Web page: https://patentgrep.com/patent/US20220275342A1

## CPC

- C12N 5/0691: {Vascular smooth muscle cells; 3D culture thereof, e.g. models of blood vessels}
- A61L 27/38: {containing added animal cells (organs or tissue containing native cells A61L27/36)}
- A61L 27/52: Hydrogels or hydrocolloids
- C12M 21/08: {for producing artificial tissue or for ex-vivo cultivation of tissue (prostheses A61F2/00, grafts A61L27/00)}
- C12M 23/20: {Material Coatings (immunocoatings C12M25/00)}
- C12M 25/14: {Scaffolds; Matrices (in general C12N5/0068)}
- C12M 29/00: {Means for introduction, extraction or recirculation of materials, e.g. pumps (pumps per se F04B)}
- C12M 29/10: {Perfusion}
- C12N 2501/115: Basic fibroblast growth factor (bFGF, FGF-2)
- C12N 2501/135: Platelet-derived growth factor [PDGF]
- C12N 2501/165: Vascular endothelial growth factor [VEGF]
- C12N 2513/00: 3D culture
- C12N 2533/40: Polyhydroxyacids, e.g. polymers of glycolic or lactic acid (PGA, PLA, PLGA); Bioresorbable polymers
- C12N 2533/74: Alginate
- C12N 2539/00: Supports and/or coatings for cell culture characterised by properties
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- C12M: APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; {APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS}

## Abstract

Embodiments of the disclosure provide a dissolvable or degradable artificial circulation system for engineering, culturing, and integrating large volume tissues. Also provided are methods of using large engineered tissues prepared using the degradable artificial circulation system for clinical applications and for various applications such as large-scale production of therapeutic or consumable products, drug discovery, and toxicity screening.

## Claims

### Claim 1

A method for preparing a large engineered tissue, the method comprising
(a) seeding cells onto a three-dimensional scaffold comprising one or more hollow biomaterial tubes, each tube comprising a first tube end and a second tube end;
(b) circulating a culture medium through the hollow biomaterial tubes, wherein circulating comprising forming a fluid circuit between the one or more hollow biomaterial tubes and a directional fluid pumping device comprising a first inlet, a second inlet, and a reservoir, wherein the first tube end is in fluid contact with the first inlet and the second tube end is in fluid contact with the second inlet, and wherein the first and second inlets introduce the culture medium from the reservoir into one or more hollow biomaterial tubes; and
(c) culturing the seeded scaffold under conditions that promote one or more of proliferation, differentiation, and maturation of the seeded cells to form an engineered tissue having a thickness greater than 1 mm in at least one dimension.

### Claim 2 (depends on 1)

The method of claim 1, wherein the scaffold comprises a plurality of hollow biomaterial tubes, each hollow biomaterial tube spaced apart to support efficient nutrient diffusion throughout the whole engineered tissue.

### Claim 3 (depends on 1)

The method of claim 1, wherein the cells are cell spheroids and seeding comprises placing the cell spheroids between hollow biomaterial tubes of the scaffold.

### Claim 4 (depends on 1)

The method of claim 1, wherein seeding comprises placing single cells adjacent to an outer surface of the one or more hollow biomaterial tubes.

### Claim 5 (depends on 4)

The method of claim 4, wherein the outer surface of the one or more hollow biomaterial tubes comprises cell adhesion molecules.

### Claim 6 (depends on 1)

The method of claim 1, wherein the hollow biomaterial tubes comprise a hydrogel.

### Claim 7 (depends on 6)

The method of claim 6, wherein the hydrogel is degradable.

### Claim 8 (depends on 1)

The method of claim 1, wherein the hollow biomaterial tubes comprise alginate.

### Claim 9 (depends on 8)

The method of claim 8, wherein the alginate comprises alginate acid polymers, sodium alginate polymers, or modified alginate polymers, or combinations thereof.

### Claim 10 (depends on 8)

The method of claim 8, wherein the alginate is dissolvable.

### Claim 11 (depends on 1)

The method of claim 1, wherein the 3D scaffold is seeded with cells.

### Claim 12 (depends on 11)

The method of claim 11, wherein the cells are selected from embryonic stem cells, induced pluripotent stem cells, cells differentiated from embryonic stem cells or induced pluripotent stem cells, cells reprogrammed from other cell types, primary cells, endothelial cells, umbilical vein endothelial cells, vascular smooth muscle cells, cancer cells, T cells, tissue stem cells, mammalian cells, plant cells, yeast, and bacterial cells, or a combination thereof.

### Claim 13 (depends on 1)

The method of claim 1, further comprising seeding the hollow biomaterial tubes with cells.

### Claim 14 (depends on 13)

The method of claim 13, wherein the cells comprise endothelial cells, vascular smooth muscle cells, or a combination thereof.

### Claim 15 (depends on 13)

The method of claim 13, wherein the hollow biomaterial tubes are further seeded with growth factors.

### Claim 16 (depends on 13, 14, 15)

The method of any of claims 13-15, wherein the engineered tissue comprises blood vessels.

### Claim 17

An artificial tissue circulation system, the system comprising
(a) a directional fluid pumping device having a first inlet, a second inlet, and a reservoir; and
(b) a three-dimensional (3D) biocompatible scaffold comprising one or more hollow biomaterial tubes, each tube comprising a first end and a second end, wherein the first end is in fluid contact with the first inlet and the second end is in fluid contact with the second inlet, and wherein the first and second inlets are operable for introducing a fluid from the reservoir into the hollow biomaterial tube, thereby forming a fluid circuit between the directional fluid pumping device and the hollow biomaterial tube.

### Claim 18 (depends on 17)

The system of claim 17, wherein the scaffold comprises a plurality of substantially parallel hollow biomaterial tubes.

### Claim 19 (depends on 17)

The system of claim 17, wherein the hollow biomaterial tube comprises a hydrogel.

### Claim 20 (depends on 19)

The system of claim 19, wherein the hydrogel comprises alginate.

### Claim 21 (depends on 18)

The system of claim 18, wherein the alginate comprises alginate acid polymers, sodium alginate polymers, or modified alginate polymers, or combinations thereof.

### Claim 22 (depends on 17)

The system of claim 17, wherein the 3D scaffold is seeded with cells.

### Claim 23 (depends on 22)

The system of claim 22, wherein the cells are selected from embryonic stem cells, induced pluripotent stem cells, cells differentiated from embryonic stem cells or induced pluripotent stem cells, cells reprogrammed from other cell types, primary cells, endothelial cells, umbilical vein endothelial cells, vascular smooth muscle cells, cancer cells, T cells, tissue stem cells, mammalian cells, plant cells, yeast and bacterial cells, or a combination thereof.

### Claim 24 (depends on 17)

The system of claim 17, wherein the reservoir comprises a cell culture medium.
